

Smoking/Lung Cancer Plan Of Action

Posted on September 30, 2019

Abstract

Continuing to smoke after a lung-cancer diagnosis can worsen treatment response, increase treatment toxicity, raise the risk of additional cancers, and reduce survival. Quitting remains beneficial even after years of smoking and should be treated as an essential component of cancer care rather than a moral test of the patient. This paper presents an evidence-based smoking-cessation plan of action for a hypothetical patient with lung cancer. The plan combines respectful assessment, motivational interviewing, behavioral counseling, medication review, coordination with oncology, management of withdrawal, social support, relapse prevention, and follow-up. It emphasizes that nicotine dependence is a chronic, relapsing condition influenced by biology, habit, stress, and environment. Effective counseling should avoid shame and should respect the patient's readiness, values, symptoms, and treatment priorities. Pharmacotherapy may include nicotine-replacement therapy, varenicline, or bupropion when clinically appropriate, but selection must be made by qualified healthcare professionals who know the patient's medical history and current treatment. The proposed framework uses the Ask-Advise-Assess-Assist-Arrange model and integrates palliative and psychosocial needs. It is educational and does not replace individualized medical care.

Introduction

A diagnosis of lung cancer can create fear, grief, guilt, anger, and uncertainty. A patient who smokes may simultaneously want to quit and depend on cigarettes to manage stress. Family members or professionals may respond with blame, but shame rarely improves dependence treatment and can weaken trust.

Smoking cessation remains clinically important after diagnosis. The Centers for Disease Control and Prevention reports that continued smoking among people with cancer is associated with poorer treatment response, greater toxicity, recurrence risk, additional primary cancers, and mortality. Quitting can improve prognosis and quality of life (CDC, 2024).

This paper develops a plan for a hypothetical client, Sven, who has lung cancer and continues to smoke. The approach is collaborative and trauma-informed. It argues that cessation support should be offered repeatedly, combined with medical treatment, and adapted to the patient's goals rather than delivered as a one-time instruction.

Establishing a Therapeutic Foundation

The first meeting should communicate respect and partnership. The counselor introduces their role, confirms how the patient wishes to be addressed, explains confidentiality and its limits, and asks permission to discuss tobacco use.

Body language should be open, but professional conduct is more important than performative friendliness. The counselor should not assume that a handshake, eye contact, or a particular communication style is preferred. Cultural practices, infection precautions, physical discomfort, and individual preference matter.

An opening statement might be: “Many people find smoking especially difficult to stop during cancer treatment. I would like to understand what it does for you and discuss options that may make quitting more manageable. Would that be all right?” This wording normalizes dependence without minimizing risk.

Assessment of Tobacco Use

The counselor should obtain a practical tobacco history:

- Current number of cigarettes and pattern across the day
- Time from waking to the first cigarette
- Years of use and previous changes
- Past quit attempts, duration, methods, and reasons for relapse
- Use of vaping products, cigars, smokeless tobacco, cannabis, or other substances
- Situations, emotions, people, and routines that trigger smoking
- Withdrawal symptoms and perceived benefits of smoking
- Exposure of household members to smoke

Assessment also includes depression, anxiety, alcohol use, pain, sleep, cognitive symptoms, financial stress, housing, and social support. Suicidal thoughts require immediate clinical evaluation according to local procedures.

The counselor should review cancer type, stage, treatment, medications, cardiovascular history, seizure risk, kidney function, and other conditions through coordination with the medical team. Counselors should not independently prescribe or alter medication.

Explaining Benefits Without Blame

Patients may believe that quitting is pointless because cancer has already developed. The counselor should correct this misconception clearly and compassionately. Quitting can improve circulation and

respiratory symptoms and may improve cancer outcomes. Prospective evidence in early-stage lung cancer has associated quitting after diagnosis with longer survival and delayed disease progression compared with continued smoking (Sheikh et al., 2021).

Benefits should be personalized. Sven may care about tolerating treatment, breathing more comfortably, spending time with family, reducing expense, or feeling greater control. Information is more motivating when connected to the patient's own priorities.

The counselor should avoid implying that smoking alone caused the individual's illness. Smoking is the major preventable cause of lung cancer, but individual disease results from interacting exposures and susceptibility. Treatment should not be conditional on moral approval.

Assessing Readiness

Readiness is not simply "motivated" or "unmotivated." A patient may want to quit but fear withdrawal, failure, or the loss of a coping strategy. Questions can explore importance and confidence:

- "On a scale from 0 to 10, how important is quitting to you now?"
- "Why did you choose that number rather than a lower one?"
- "What would increase your confidence by one point?"

Motivational interviewing emphasizes collaboration, evocation, acceptance, and compassion (Miller & Rollnick, 2013). The counselor listens for the patient's reasons for change and avoids arguing. Resistance often signals that the conversation is moving faster than the patient.

Setting a Goal

Complete cessation is the recommended goal because no safe level of cigarette smoking exists. If Sven is ready, a quit date can be selected soon enough to maintain momentum while allowing preparation. The date may be coordinated with treatment and medical advice.

If he is not ready for a quit date, the plan should still include a concrete next step: monitoring cigarettes, delaying the first cigarette, establishing smoke-free spaces, or trying medication-supported reduction under clinical guidance. Reduction may lower exposure but is not equivalent to quitting. The conversation should remain open.

Pharmacotherapy

Medication can reduce withdrawal and increase the likelihood of cessation. Common options for adults include nicotine-replacement therapy, varenicline, and bupropion. Selection depends on medical

history, patient preference, previous response, availability, interactions, and clinician judgment.

Nicotine-replacement therapy provides nicotine without combustion products. A long-acting patch may be combined with a short-acting form such as gum or lozenge for breakthrough craving. Correct use is important; underdosing can leave withdrawal untreated.

Varenicline acts at nicotinic receptors and can reduce craving and the rewarding effect of smoking. Bupropion can reduce withdrawal and may be useful for some patients. Each has contraindications, precautions, and possible adverse effects. The oncology or prescribing team should evaluate suitability, particularly when the patient has complex illness or multiple medications.

The risk of approved cessation medication is generally much lower than continued cigarette smoking, but this broad comparison does not replace patient-specific assessment.

Behavioral Counseling

Medication addresses dependence physiology, while counseling addresses habits, cues, coping, and meaning. Combined treatment is generally more effective than either alone.

Sven can track each cigarette for several days, recording time, location, emotion, activity, and urge. Patterns often reveal automatic smoking with coffee, driving, meals, telephone calls, or distress.

For each high-risk situation, the plan identifies an alternative. After meals, he might brush his teeth or walk briefly if medically able. During a craving, he can use prescribed short-acting nicotine replacement, paced breathing, water, a support call, or a short distraction. Cravings usually rise and fall rather than continuing at peak intensity indefinitely.

Managing Withdrawal

Withdrawal may include irritability, anxiety, restlessness, difficulty concentrating, low mood, increased appetite, and sleep disturbance. Cancer symptoms or treatment effects may overlap, making clinical communication important.

The counselor should prepare Sven and family members so symptoms are not interpreted as personal failure. Medication adjustment, sleep support, nutrition advice, and mental-health treatment may be needed. Severe or unusual symptoms should be reported promptly.

Withdrawal management should be proactive. Waiting until the patient is overwhelmed increases relapse risk.

Environmental Change

The home and daily routine can support cessation. Cigarettes, lighters, and ashtrays should be removed when the patient is ready. Cars and indoor spaces should become smoke-free. Clothing and furniture may retain odor and function as cues.

Household members who smoke should be invited to seek treatment or, at minimum, avoid smoking around Sven and avoid offering cigarettes. Support should not become surveillance or punishment. The patient needs encouragement and practical help rather than constant questioning.

Stress, Grief, and Cancer-Related Emotions

Smoking may regulate distress temporarily. Removing it without replacing its function can leave the patient vulnerable. Counseling should address fear of death, body changes, pain, financial pressure, family conflict, and uncertainty.

Appropriate referrals may include oncology social work, psychology, psychiatry, spiritual care, support groups, financial navigation, or palliative care. Palliative care can be provided alongside active cancer treatment and focuses on symptoms and quality of life.

Relaxation methods should match ability and preference. Brief breathing exercises, guided imagery, music, gentle activity, and structured problem-solving may help. Claims that positive thinking alone treats cancer should be rejected.

Communication With the Oncology Team

Tobacco treatment should be documented in the cancer-care plan. The team should know the quit date, medications, withdrawal concerns, and progress. Repeated advice from different professionals is helpful when it is coordinated rather than contradictory.

Electronic health records can prompt assessment and referral, but a checkbox is not treatment. Someone must own follow-up. Cancer centers can use an opt-out model in which all patients who use tobacco are automatically offered evidence-based services.

Relapse Prevention

A lapse is one cigarette or brief return; relapse is a return to regular smoking. A lapse should trigger analysis rather than shame. The counselor asks what happened, what the cigarette appeared to provide, and what protection was missing.

High-risk periods may include treatment results, hospitalization, alcohol use, contact with smokers, pain, and family conflict. Plans should be rehearsed. Medication should not be stopped automatically after a lapse without clinician advice.

Multiple attempts are common in nicotine dependence. Each attempt can provide information that improves the next plan.

Follow-Up Schedule

Time	Primary focus
Initial visit	Assessment, readiness, education, medical coordination
Before quit date	Medication plan, trigger preparation, environmental change
Within 2–3 days after quitting	Withdrawal, correct medication use, immediate problem-solving
One week	Cravings, mood, treatment symptoms, reinforcement
Two to four weeks	Medication review, routines, social support, lapse prevention
During cancer transitions	Reassess after scans, treatment changes, hospitalization, or recurrence
Long term	Maintain abstinence, address occasional urges, celebrate health goals

Sample Collaborative Plan

After assessment, Sven and the team might agree on the following: select a quit date within two weeks; obtain approval for a combination medication plan; make the home and car smoke-free; tell two trusted supporters how they can help; use a written coping response for morning, meal, and stress triggers; schedule a follow-up within three days of quitting; and contact the oncology team if mood, breathing, or treatment symptoms worsen.

The plan should be written in plain language and revised with Sven. Success includes engagement and learning, not only perfect abstinence on the first attempt.

Ethical Considerations

Autonomy requires informed choice, not abandonment. Clinicians should strongly recommend quitting and offer treatment while respecting the patient's right to decide. Beneficence supports active assistance because cessation improves health. Nonmaleficence requires safe medication review and attention to psychological distress.

Justice requires access. Patients with low income, limited transport, unstable housing, or inadequate insurance may face greater exposure and fewer treatment resources. Programs should provide accessible medication and counseling rather than blaming individuals for structural barriers.

Conclusion

Smoking cessation after a lung-cancer diagnosis is worthwhile and should be integrated into oncology care. The most effective plan combines clear medical advice with empathy, medication when appropriate, behavioral counseling, environmental support, and repeated follow-up.

Sven should not be treated as a person who merely refuses good advice. Nicotine dependence is sustained by neurobiology, habit, stress, and social context. A collaborative counselor seeks to understand those mechanisms and help the patient build alternatives.

The goal is complete cessation, but the process must remain compassionate and clinically coordinated. Quitting can improve prognosis and restore a sense of agency during a period when much of life feels outside the patient's control. Every visit is an opportunity to assist, not to judge.

References

Centers for Disease Control and Prevention. (2024). *Cancer care settings and smoking cessation*.

Fiore, M. C., Jaén, C. R., Baker, T. B., et al. (2008). *Treating tobacco use and dependence: 2008 update*. U.S. Department of Health and Human Services.

Miller, W. R., & Rollnick, S. (2013). *Motivational interviewing: Helping people change* (3rd ed.). Guilford Press.

National Cancer Institute. (2017). *Harms of cigarette smoking and health benefits of quitting*.

Sheikh, M., Mukeriyah, A., Shangina, O., Brennan, P., & Zaridze, D. (2021). Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality. *Annals of Internal Medicine*, 174(9), 1232-1239. <https://doi.org/10.7326/M21-0252>

U.S. Preventive Services Task Force. (2021). Interventions for tobacco smoking cessation in adults.

JAMA, 325(3), 265–279. <https://doi.org/10.1001/jama.2020.25019>